The oral therapeutic that could change our approach to retinal disease

News
Article
Ophthalmology Times EuropeOphthalmology Times Europe October 2023
Volume 19
Issue 08
Pages: 27

An inflammation-based view of both ophthalmic and neurologic health

A man wearing glasses prepares to take medication in pill form. Image credit: ©Andrii Zastrozhnov – stock.adobe.com

Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. Image credit: ©Andrii Zastrozhnov – stock.adobe.com

In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Breye Therapeutics ApS announced their collaboration to develop the P2X7 receptor antagonist programme. Breye Therapeutics, a clinical-stage pharmaceutical company focused on the development of novel oral therapies for retinal diseases, described the P2X7 receptor as “an ATP-gated ion channel” and “a key inflammation switch.”1 Inflammation is a major aspect of the pathogenesis of diabetic retinopathy (DR) as well as age-related macular degeneration (AMD), primary causes of vision loss among working-age and elderly adults.

Gabriela Burian, MD, a member of the Breye Therapeutics board of directors, said the P2X7 receptor antagonist programme follows the lead of similar research in neuroscience, immunology and inflammatory diseases like rheumatoid arthritis. “Biologically, the cellular cascade of inflammatory cytokines occurs in all these tissues, as well as in the retina,” Dr Burian said. “In the retina, that means cellular incapacity to perform its function, which ultimately leads to vision loss.” Dr Burian said a treatment model that borrows from existing inflammation-based protocols could help ophthalmologists execute earlier interventions in AMD and DR. “Macular degeneration and diabetic retinopathy can be diagnosed and are diagnosed before [vision loss], with signs of inflammation represented by small vascular leakages and hemorrhages, lipid deposits and areas of atrophy. But there are no treatments yet for these disease stages,” she said.

Dr Burian referenced patient groups impacted by DR- and AMD-related vision loss to demonstrate the benefits of an oral therapeutic for retina care. In the case of both populations, consistent access to existing treatment protocols can be stymied by many factors. “Oftentimes the treatment is not received because the patient cannot make it to the clinic for reasons unrelated to the disease, but centred around their social situation,” Dr Burian said.

For many patients with AMD, access to a clinic is dependent on family members or social services, which can be inconsistent. Patients with diabetes are often juggling other medical appointments while trying to treat retinopathy, placing considerable strain on their schedules and budgets. “These are multimedicated patients, and they have difficult things to prioritise,” she said.

With these accessibility benefits in mind, Dr Burian said, oral therapies can also function in conjunction with therapies currently on the market. “They’re likely to be complementary with anti-VEGFs and complement inhibitors, as current therapies address a different biological pathway and disease stages,” she said. She also emphasised that the interventional opportunities created by neurology’s “biological overlap” with ophthalmology extend beyond molecular therapies like P2X7.

Other cross-specialty developments, such as in the imaging space, serve to further optimise the DR/AMD treatments as well as patient burden reduction.

Reference

1. Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer. Breye Therapeutics. Published 25 July, 2023; Accessed 15 August, 2023. https://golgineurosciences.com/golgi-neurosciences-and-breye-therapeutics-announce-successful-closing-of-p2x7-receptor-antagonist-program-transfer/

Gabriela Burian, MD

Dr Burian has over 25 years of experience in clinical research, including former positions at Roche and Novartis. She is a member of the Board of Directors at Breye Therapeutics.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.